Free Trial

Soleno Therapeutics (SLNO) Insider Trading & Ownership

Soleno Therapeutics logo
$57.78 +3.15 (+5.77%)
(As of 11/22/2024 ET)

Soleno Therapeutics (NASDAQ:SLNO) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
12.30%
Number Of
Insiders Buying
(Last 12 Months)
0
Number Of
Insiders Selling
(Last 12 Months)
6
Amount Of
Insider Selling
(Last 12 Months)
$82.47 M
Get SLNO Insider Trade Alerts

Want to know when executives and insiders are buying or selling Soleno Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

SLNO Insider Buying and Selling by Quarter

Soleno Therapeutics Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/1/2024Bhatnagar AnishCEOSell21,633$49.43$1,069,319.19  
10/1/2024James H MackanessCFOSell8,077$49.43$399,246.11  
10/1/2024Kristen YenInsiderSell3,108$49.43$153,628.44  
8/29/2024Vivo Opportunity, LlcMajor ShareholderSell100,000$47.22$4,722,000.00  
8/28/2024Bhatnagar AnishCEOSell56,613$47.58$2,693,646.54  
8/28/2024James H MackanessCFOSell6,661$47.58$316,930.38  
8/28/2024Kristen YenInsiderSell5,270$47.58$250,746.60  
8/27/2024Vivo Opportunity, LlcMajor ShareholderSell500,000$48.73$24,365,000.00  
8/5/2024Bhatnagar AnishCEOSell58,213$45.77$2,664,409.01  
8/5/2024James H MackanessCFOSell6,849$45.77$313,478.73  
8/5/2024Kristen YenInsiderSell5,017$45.77$229,628.09  
7/1/2024Bhatnagar AnishCEOSell19,256$41.54$799,894.24  
7/1/2024James H MackanessCFOSell7,190$41.54$298,672.60  
7/1/2024Kristen YenInsiderSell2,170$41.54$90,141.80  
4/29/2024Vivo Opportunity, LlcMajor ShareholderSell750,000$47.80$35,850,000.00  
4/1/2024Bhatnagar AnishCEOSell18,980$41.34$784,633.20  
4/1/2024James H MackanessCFOSell5,175$41.34$213,934.50  
4/1/2024Kristen YenInsiderSell2,218$41.34$91,692.12  
1/25/2024Bhatnagar AnishCEOSell2,527$48.30$122,054.10  
1/25/2024Kristen YenInsiderSell397$48.30$19,175.10  
12/13/2023Kristen YenInsiderSell17,916$37.76$676,508.16  
12/11/2023Bhatnagar AnishCEOSell93,408$35.67$3,331,863.36  
12/11/2023James H MackanessCFOSell32,482$36.41$1,182,669.62  
11/30/2023Bhatnagar AnishCEOSell27,716$28.65$794,063.40  
11/30/2023James H MackanessCFOSell4,186$28.65$119,928.90  
11/29/2023Kristen YenInsiderSell3,979$27.83$110,735.57  
11/28/2023Bhatnagar AnishCEOSell25,678$27.12$696,387.36  
11/28/2023James H MackanessCFOSell3,878$27.12$105,171.36  
(Data available from 1/1/2013 forward)

SLNO Insider Trading Activity - Frequently Asked Questions

The list of insiders at Soleno Therapeutics includes Bhatnagar Anish, Jack W Schuler, James H Mackaness, Kristen Yen, Perceptive Advisors Llc, and Vivo Opportunity, Llc. Learn more on insiders at SLNO.

12.30% of Soleno Therapeutics stock is owned by insiders. Learn more on SLNO's insider holdings.

The following insider purchased SLNO shares in the last 24 months: Perceptive Advisors Llc ($16,231,728.24).

Insiders have purchased a total of 1,070,257 SLNO shares in the last 24 months for a total of $16,231,728.24 bought.

The following insiders have sold SLNO shares in the last 24 months: Bhatnagar Anish ($12,956,270.40), James H Mackaness ($2,950,032.20), Kristen Yen ($1,622,255.88), and Vivo Opportunity, Llc ($64,937,000.00).

Insiders have sold a total of 1,788,597 Soleno Therapeutics shares in the last 24 months for a total of $82,465,558.48 sold.

Soleno Therapeutics Key Executives

  • Dr. Anish Bhatnagar M.D. (Age 54)
    President, CEO, COO & Director
    Compensation: $1.06M
  • Mr. James H. MacKanessMr. James H. MacKaness (Age 60)
    Chief Financial Officer
    Compensation: $640k
    4 recent trades
  • Ms. Patricia C. Hirano M.P.H. (Age 58)
    Senior Vice President of Regulatory Affairs
    Compensation: $493k
  • Ms. Lauren Budesheim
    Vice President of People
  • Ms. Kristen Yen M.S. (Age 55)
    Senior Vice President of Clinical Operations
    Compensation: $317.19k
    4 recent trades
  • Dr. Neil M. Cowen M.B.A.
    Ph.D., Senior Vice President of Drug Development
  • Ms. Meredith Manning M.B.A. (Age 52)
    Chief Commercial Officer
  • Dr. Michael Huang M.D. (Age 50)
    Senior Vice President of Clinical Development


This page (NASDAQ:SLNO) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners